Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00761020 · ClinicalTrials.gov registry record · NA

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

A NA study of Malaria, sponsored by U.S. Army Medical Research and Development Command.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT00761020 is a NA study of Malaria that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 31 participants, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00761020, a NA study of Malaria, has completed, sponsored by U.S. Army Medical Research and Development Command.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this trial is to study whether a certain blood test can reliably identify the presence of malaria in people who have been infected with, but who do not have symptoms of malaria.

Conditions Studied

Interventions

  • OTHER Control
  • DRUG Mefloquine

Study Locations (1)

Maryland

  • Walter Reed Army Institute of Research - Silver Spring

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2008-09
Est. Completion 2009-12
Phase NA

What the Registry Record Tells You About NCT00761020

The ClinicalTrials.gov registry entry for NCT00761020 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (88% lower). The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.

NCT00761020 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00761020 about?

NCT00761020 is a clinical study titled "Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection". The main purpose of this trial is to study whether a certain blood test can reliably identify the presence of malaria in people who have been infected with, but who do not have symptoms of malaria.

What is the current status of trial NCT00761020?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2008-09. Estimated completion is 2009-12.

What conditions does trial NCT00761020 study?

This clinical trial studies the following conditions: Malaria.

What interventions are being tested in trial NCT00761020?

The interventions under investigation include: Control (OTHER), Mefloquine (DRUG).

Who is sponsoring clinical trial NCT00761020?

This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00761020 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malaria

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.